0HOJ logo

Blueprint Medicines LSE:0HOJ Stock Report

Last Price

US$100.42

Market Cap

US$6.4b

7D

11.3%

1Y

72.9%

Updated

08 Nov, 2024

Data

Company Financials +

Blueprint Medicines Corporation

LSE:0HOJ Stock Report

Market Cap: US$6.4b

0HOJ Stock Overview

A precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.

0HOJ fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Blueprint Medicines Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Blueprint Medicines
Historical stock prices
Current Share PriceUS$100.42
52 Week HighUS$121.20
52 Week LowUS$56.93
Beta0.59
11 Month Change14.75%
3 Month Change9.09%
1 Year Change72.92%
33 Year Change-12.66%
5 Year Change33.89%
Change since IPO20.97%

Recent News & Updates

Recent updates

Shareholder Returns

0HOJGB BiotechsGB Market
7D11.3%-6.1%-1.3%
1Y72.9%-17.6%8.0%

Return vs Industry: 0HOJ exceeded the UK Biotechs industry which returned -17.7% over the past year.

Return vs Market: 0HOJ exceeded the UK Market which returned 7.6% over the past year.

Price Volatility

Is 0HOJ's price volatile compared to industry and market?
0HOJ volatility
0HOJ Average Weekly Movement5.7%
Biotechs Industry Average Movement8.8%
Market Average Movement4.7%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0HOJ has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0HOJ's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008638Kate Havilandwww.blueprintmedicines.com

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.

Blueprint Medicines Corporation Fundamentals Summary

How do Blueprint Medicines's earnings and revenue compare to its market cap?
0HOJ fundamental statistics
Market capUS$6.44b
Earnings (TTM)-US$128.05m
Revenue (TTM)US$434.42m

14.7x

P/S Ratio

-50.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HOJ income statement (TTM)
RevenueUS$434.42m
Cost of RevenueUS$12.93m
Gross ProfitUS$421.48m
Other ExpensesUS$549.53m
Earnings-US$128.05m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.02
Gross Margin97.02%
Net Profit Margin-29.48%
Debt/Equity Ratio206.9%

How did 0HOJ perform over the long term?

See historical performance and comparison